A randomized phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma.
about
Critical appraisal of IFN-alpha-based adjuvant therapy in stage II-III malignant melanoma.A phase II trial of nab-paclitaxel (ABI-007) and carboplatin in patients with unresectable stage IV melanoma : a North Central Cancer Treatment Group Study, N057E(1)State of melanoma: an historic overview of a field in transition.Melanoma: a model for testing new agents in combination therapies.The history and future of chemotherapy for melanoma.Efficacy and safety of HLA-B7/beta-2 microglobulin plasmid DNA/lipid complex (Allovectin-7) in patients with metastatic melanoma.A natural bacterial-derived product, the metalloprotease arazyme, inhibits metastatic murine melanoma by inducing MMP-8 cross-reactive antibodies.The emerging role of the thrombin receptor (PAR-1) in melanoma metastasis--a possible therapeutic target.Therapeutic interventions to disrupt the protein synthetic machinery in melanomaCombination chemotherapy with or without s.c. IL-2 and IFN-alpha: results of a prospectively randomized trial of the Cooperative Advanced Malignant Melanoma Chemoimmunotherapy Group (ACIMM)Systemic therapy of disseminated malignant melanoma: an evidence-based overview of the state-of-the-art in daily routine.Immunotherapy of distant metastatic disease.Molecular targeted therapy for patients with melanoma: the promise of MAPK pathway inhibition and beyond.Sorafenib in melanoma.A(2B) and A(3) adenosine receptors modulate vascular endothelial growth factor and interleukin-8 expression in human melanoma cells treated with etoposide and doxorubicin.
P2860
Q33184877-39A37571-F693-4FF6-BEFF-CDDD0096B691Q33394828-ACA53816-A8C6-455A-AE90-F6430AD36197Q33693906-7CA66FA9-2E61-4A9C-A25B-4098F27800ABQ33863916-F8C72B97-5ED2-48F9-B522-7898A32017F4Q34608084-EFB002BB-757C-4A00-9779-DEBBAFDB415EQ35093647-7E2F11DA-C68B-4974-8027-3E2937D0BCD0Q35161541-C21AD487-CE37-4FC2-964B-002366893F18Q35640140-7101E3BC-1010-4873-AB85-3D9A00284049Q36473355-AC73FC5B-775A-4682-AD9E-1E63B2BA08BBQ36643649-2E54E0C0-35A8-4DE3-8FF7-D141A9BA604FQ36980823-B9D059C1-7FF6-429F-AA8F-C9E05392F064Q37266668-16201895-76BD-416E-B40A-E07BE1167F46Q37778064-9E1D9541-648C-4EEB-B2A2-B40731758263Q37990977-BEBFF785-8D66-4A28-B382-4D8EA99120DDQ39793029-10E35C3C-ECB6-41B3-BBD3-3D9DEA1D7263
P2860
A randomized phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
2000年论文
@zh
2000年论文
@zh-cn
name
A randomized phase III study c ...... terferon in advanced melanoma.
@ast
A randomized phase III study c ...... terferon in advanced melanoma.
@en
type
label
A randomized phase III study c ...... terferon in advanced melanoma.
@ast
A randomized phase III study c ...... terferon in advanced melanoma.
@en
prefLabel
A randomized phase III study c ...... terferon in advanced melanoma.
@ast
A randomized phase III study c ...... terferon in advanced melanoma.
@en
P2093
P2860
P356
P1476
A randomized phase III study c ...... terferon in advanced melanoma.
@en
P2093
Ashcroft L
Middleton MR
Thatcher N
P2860
P2888
P304
P356
10.1054/BJOC.1999.1056
P407
P577
2000-03-01T00:00:00Z
P5875
P6179
1053146876